Sensorium Therapeutics

Thriving by nature.

Add To Watchlist
General Information
Company Name
Sensorium Therapeutics
Founded Year
2021
Location (Offices)
Boston, United States +1
Founders / Decision Makers
Richard Simon - Co-Founder & Board Member Alex Simon - Co-Founder & Chief of Staff Jeffrey M. Brown - Chief Scientific Officer Alexandra Glucksmann - President and Chief Executive Officer Sam Rasty - Chief Business Officer
Number of Employees
26
Industries
Health Care, Health and Wellness
Funding Stage
Series A
Social Media

Sensorium Therapeutics - Company Profile

Sensorium Therapeutics is a biotechnology company that was founded in 2021 by a team of world-class researchers, clinicians, and thought leaders from Massachusetts General Hospital and Harvard University. The company aims to develop nature-derived psychoactive medicines for mental health by leveraging cutting-edge chemistry, neuroscience, and machine learning. Sensorium's groundbreaking Biodynamic Discovery Platform is inspired by the real-world human benefits of plants and fungi, and it aims to reproduce, adapt, and enhance targeted molecules to elevate their utility as modern medicines. The company recently secured a $30.00M Series A investment on 04 October 2022 from a group of investors including Route 66 Ventures, Santé Ventures, CU Healthcare Innovation Fund, Iter Investments, Ocama Partners, re.Mind Capital, WPSS.bio, and Palo Santo. With its innovative approach and strong backing, Sensorium Therapeutics is well-positioned to make a significant impact in the health care industry with its nature-inspired approach to mental health. Visit sensorium.bio to learn more about the company's mission and vision.

Taxonomy: Neuroscience, Mental health, Psychoactive medicines, Nature-derived, Chemistry, Machine learning, Research, Clinical, Harvard University, Massachusetts General Hospital, Biodynamic Discovery Platform

Funding Rounds & Investors of Sensorium Therapeutics (1)

View All
Funding Stage Amount No. Investors Investors Date
Series A $30.00M 8
Route 66 Ventures, investor in Sensorium Therapeutics's Series A round Santé Ventures, investor in Sensorium Therapeutics's Series A round Iter Investments, investor in Sensorium Therapeutics's Series A round Ocama Partners, investor in Sensorium Therapeutics's Series A round re.Mind Capital, investor in Sensorium Therapeutics's Series A round WPSS.bio, investor in Sensorium Therapeutics's Series A round Palo Santo, investor in Sensorium Therapeutics's Series A round
The CU Healthcare Innovation Fund 		04 Oct 2022

Latest News of Sensorium Therapeutics

View All

No recent news or press coverage available for Sensorium Therapeutics.

Similar Companies to Sensorium Therapeutics

View All
Kalgera - Similar company to Sensorium Therapeutics
Kalgera Safeguarding financial lives
1200 Pharma - Similar company to Sensorium Therapeutics
1200 Pharma We leverage our breakthrough chemistry, cutting edge computation & data-rich models to accelerate drug discovery.
Matchpoint Therapeutics - Similar company to Sensorium Therapeutics
Matchpoint Therapeutics Acing the future of covalent medicines
Vilya - Similar company to Sensorium Therapeutics
Vilya Compute Beyond Nature
Solvemed Limited - Similar company to Sensorium Therapeutics
Solvemed Limited Revolutionising neurology diagnostics and drug discovery with the power of Artificial Intelligence.
Circle Decoration Circle Decoration

Want to dive deeper into Sensorium Therapeutics? Join now to access exclusive insights and find similar companies like this — powered by AI analytics.

Register Now